Zymeworks BC Inc.: Clinical Trials

4 trials sponsored by Zymeworks BC Inc., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 recruiting, 1 terminated. 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 14Active not recruiting 1, Completed 1, Recruiting 1, Terminated 1

Follow Zymeworks BC Inc.: new trials by email

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of ZW251 in Participants With Advanced Solid Tumors
ZW251 - Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer
Phase 1RecruitingZymeworks BC Inc.1402025-10-212026-10-05
A Study of ZW191 in Participants With Solid Tumors
ZW191 - Advanced Solid Tumors
Phase 1Active not recruitingZymeworks BC Inc.1452024-10-302026-05-07
A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
ZW171 - Mesothelin-expressing Advanced Cancers
Phase 1TerminatedZymeworks BC Inc.322024-09-302025-10-21
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
ZW49 - HER2-expressing Cancers
Phase 1CompletedZymeworks BC Inc.1122019-04-152025-01-29

Conditions studied

Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Breast Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Cholangiocarcinoma (1)  ·  Colorectal Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Neoplasms, Germ Cell and Embryonal (1)  ·  Neoplasms, Squamous Cell (1)  ·  Ovarian Neoplasms (1)  ·  Stomach Neoplasms (1)

Countries

United States (4)  ·  South Korea (3)  ·  Australia (2)  ·  Japan (2)  ·  Spain (2)  ·  Canada (1)  ·  Germany (1)  ·  Ireland (1)  ·  Portugal (1)  ·  Singapore (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Maggie Weinstein, MD, PhD, MPH (2)  ·  Joseph Woolery, PharmD, BCOP (1)  ·  Pranshul Chauhan, MSc, MB, BCh, BAO (1)

NIH funding

2025 (1)